Comparative Pharmacology
Head-to-head clinical analysis: ADRUCIL versus GEMCITABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADRUCIL versus GEMCITABINE.
ADRUCIL vs GEMCITABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorouracil (5-FU) is a pyrimidine analog that inhibits thymidylate synthase, interfering with DNA synthesis. It is metabolized to its active metabolites, which incorporate into RNA and DNA, causing cytotoxicity primarily in S-phase cells.
Gemcitabine is a nucleoside analog (2',2'-difluorodeoxycytidine) that is phosphorylated intracellularly to active diphosphate (dFdCDP) and triphosphate (dFdCTP) metabolites. dFdCDP inhibits ribonucleotide reductase, reducing deoxynucleotide pools for DNA synthesis. dFdCTP competes with deoxycytidine triphosphate for incorporation into DNA, causing masked chain termination and inhibiting DNA polymerase and repair.
12 mg/kg IV bolus daily for 4 days, then if no toxicity, 6 mg/kg IV on days 6, 8, 10, and 12; or 15 mg/kg IV weekly; or 500-600 mg/m2 IV every 3-4 weeks.
1000-1250 mg/m² intravenously over 30 minutes on days 1 and 8 of a 21-day cycle.
None Documented
None Documented
Clinical Note
moderateGemcitabine + Digoxin
"Gemcitabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGemcitabine + Digitoxin
"Gemcitabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGemcitabine + Deslanoside
"Gemcitabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGemcitabine + Acetyldigitoxin
"Gemcitabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Biphasic elimination: initial t1/2α ~10-20 minutes, terminal t1/2β ~20-24 hours. Accumulation occurs with continuous infusion.
Terminal elimination half-life for gemcitabine is 42-94 minutes (mean ~57 min) in plasma; for its metabolite dFdU, the half-life is 14-74 hours (mean ~40 h), which accumulates with repeated dosing and may contribute to prolonged systemic exposure.
Primarily hepatic metabolism; renal excretion of metabolites accounts for ~60-80% of the dose. Unchanged fluorouracil excreted renally is <10%. Fecal excretion is minimal (<5%).
Primarily renal: ~92-98% of the dose excreted in urine, with <10% as unchanged gemcitabine and the majority as the inactive metabolite 2',2'-difluorodeoxyuridine (dFdU). Fecal excretion is minimal (<1%).
Category C
Category D/X
Antimetabolite
Antimetabolite